Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-29, 19:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-24, 04:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-21, 14:15
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-08, 20:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-07, 21:19
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-01-07, 20:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-12-03, 14:30
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-11-25, 21:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-11-25, 20:32
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2024-11-25, 19:57
